Acute Lymphoblastic Leukemia, in Relapse
Oncology·MeSH: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prevalence
8.0 / 100K
Incidence
1.8 / 100K/yr
1 drug in development·1 company·4 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| cd19-car t-cells | GH Research PLC (GHRS) |
Frequently asked questions
How many drugs are in development for Acute Lymphoblastic Leukemia, in Relapse?
BioSniper tracks 1 drug in development for Acute Lymphoblastic Leukemia, in Relapse across 1 company.
How many clinical trials target Acute Lymphoblastic Leukemia, in Relapse?
There are 4 clinical trials targeting Acute Lymphoblastic Leukemia, in Relapse tracked by BioSniper.
What is the prevalence of Acute Lymphoblastic Leukemia, in Relapse?
The estimated prevalence of Acute Lymphoblastic Leukemia, in Relapse is approximately 8.0 per 100,000 population.
Deep-dive into Acute Lymphoblastic Leukemia, in Relapse
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis